Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)

In the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (SBRT) could not be delivered. Therefore, a technique that could provide high radiation doses to tumors without increasing of risks of severe adverse effects is required.

Trial Details

NCT ID

NCT06427460

Phase

PHASE2

Sponsor

Changhai Hospital

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Central-boost ablative dose delivered by stereotactic body radiation therapy

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Aged 18-75 years.
Pathologically confirmed lung, liver, pancreas or retroperitoneal malignant tumor.
Oligometastasis in the case of metastatic tumor
the shortest diameter ≥2cm or the distance from the tumor to the organs at risk less than 5mm

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →